Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-001645-40 | EudraCT Number |
Not provided
Not provided
Not provided
The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial is an adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia. 48 patients are planned to be enrolled in Phase 2 and an estimated total of 111 patients are planned to be enrolled up to the end of Phase 3, with a randomization 2:1 Reparixin vs Control (Standard of care).
In the phase 2 segment of this study, patients are randomized 2:1 to Reparixin oral tablets 1200 mg (Group 1, active treatment) or standard of care (Group 2, control arm). In case of worsening (e.g. need of ICU and/or mechanical ventilation) after the first 24hrs, patients are offered a rescue medication with no restriction from the sponsor and fully based on their physicians' judgement.
In the phase 3 segment of this study, it is planned that patients are randomized 2:1 to Reparixin or standard of care. The Phase 3 design will be reassessed and decided based on the results of the Phase 2.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Reparixin | Experimental | Reparixin oral tablets 1200 mg TID for 7 days |
|
| Standard of care | Active Comparator | Standard of care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Reparixin | Drug | Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first. |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 2 - Percentage of Participants With Composite Endpoint of Clinical Events | Composite event is defined as the onset of at least one of the following events:
| Up to Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 2 - Percentage of Patients With Improvement in Clinical Severity Score (as Recommended by WHO for COVID Studies) of at Least Two Points | Changes in clinical severity score are defined as the time to clinical improvement of two points from the time of randomization on a seven-category ordinal scale or live discharge from the hospital, whichever came first. The seven-category ordinal scale consisted of the following: 1) not hospitalized, with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring supplemental oxygen; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, requiring high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6) hospitalized, requiring Extracorporeal Membrane Oxygenation (ECMO), invasive mechanical ventilation, or both; and 7) death. The higher the score, the worse the outcome. A subject is considered "improved" with a clinical severity score improvement of at least two points compared to randomization or live discharge from the hospital. n are the subjects improved at each time point vs baseline. |
Not provided
Inclusion Criteria:
Phase 2 Inclusion Criteria:
(1mmHg = 0.133kPa). 4. Chest imaging confirms lung involvement and inflammation. 5. Inflammatory status as documented by at least one of the following: Lactate dehydrogenase (LDH) > normal range, C-reactive protein (CRP) ≥ 100mg/L or IL-6 ≥ 40pg/mL, serum ferritin ≥ 900ng/mL, XDP >20mcg/mL.
Phase 3 Inclusion Criteria: Same as above; other criteria TBD based on Phase 2 outcomes.
Exclusion Criteria:
• Phase 2/3 Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lorenzo Piemonti, MD PhD | Ospedale San Raffaele | Principal Investigator |
| Alberto Zangrillo, MD PhD | Ospedale San Raffaele | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo | São Paulo | 05403-900 | Brazil | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35618953 | Derived | Landoni G, Piemonti L, Monforte AD, Grossi P, Zangrillo A, Bucci E, Allegretti M, Goisis G, Gavioli EM, Patel N, De Pizzol M, Pasedis G, Mantelli F. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. Infect Dis Ther. 2022 Aug;11(4):1559-1574. doi: 10.1007/s40121-022-00644-6. Epub 2022 May 26. |
Not provided
Not provided
Not provided
A total of 56 patients were screened and all of them were randomized to the assigned treatment group: 37 patients were randomised to receive Reparixin and 19 patients were randomised to receive standard of care.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Reparixin | Reparixin oral tablets 1200 mg TID for 7 days Reparixin: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first. |
| FG001 | Standard of Care | Standard of care Standard of care: Standard of care |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Reparixin (FAS) | Reparixin oral tablets 1200 mg TID for 7 days Reparixin: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Phase 2 - Percentage of Participants With Composite Endpoint of Clinical Events | Composite event is defined as the onset of at least one of the following events:
| The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data. | Posted | Number | 95% Confidence Interval | percentage of participants | Up to Day 1 |
|
Throughout the study, till day 21
The Safety set (SAF), which consisted of all randomized subjects who received at least one dose of the investigational medicinal product (IMP).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Reparixin (SAF) | Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Maria De Pizzol, BSc | Dompé Farmaceutici | +39 02 583831 | clinops@pec.dompe.it |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Apr 23, 2020 | Mar 15, 2022 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Nov 29, 2020 | Feb 16, 2022 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C490707 | reparixin |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Standard of care | Drug | Standard of care |
|
|
| At day 1, day 2, week 1, day 21(end of treatment, EOT), EOS (end of study, i.e. 7±3 days after EOT) |
| Phase 2 - Percentage of Improved Subjects in Dyspnea Severity, Assessed by Liker Scale | The severity of dyspnea can be measured through the Liker scale. The Liker scale is used as follows: the patient grades his current breathing compared to when he first started the drug (from -3 to 3). "0" = no change, "1" =minimally better, "2" =moderately better, "3" =markedly better, "-1" =minimally worse, "-2" =moderately worse, "-3" =markedly worse. The higher the score, the better the outcome. N is the number of subjects for which the evaluation of the dyspnea severity scale at each time point is available. n is the number of subjects improved at each time point in comparison with the randomization. | Baseline, day 1, day 2, week 1, day 21(end of treatment, EOT), 7±3 days after treatment period (end of study, EOS) |
| Phase 2 - Change From Baseline in Dyspnea Severity, Assessed by VAS Scale | The severity of dyspnea is measured also through the VAS scale. The VAS scale is used as follows: the patient draws a horizontal line on an axial graph (from 0 to 100) to show the degree of how he feels about breathing. The number "0" equals the worst breathing the patient has ever felt and the number "100" equals the best he has ever felt. N is the number of subjects for which the evaluation of the dyspnea severity scale at each time point is available. n is the number of subjects improved at each time point in comparison with the randomization. | Baseline, day 1, day 2, week 1, day 21(end of treatment, EOT), 7±3 days after treatment period (end of study, EOS) |
| Changes From Baseline in Body Temperature to Any Post-baseline Timepoints | Variations in the mean body temperature from baseline to any post-baseline timepoint were assessed. n is the number of subjects for which the evaluation of the body temperature at each time point is available. | Baseline, Day 1, Day 2, Week 1, EOT and EOS |
| Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to PaO2/FiO2 | Cumulative quantity of oxygen treatment (L) = Sum of all Quantity (L) in CONCOMITANT OXYGEN TREATMENT form, from randomization to time point of interest. According to PaO2/FiO2, the classification is 'mild' if 200 <= PaO2/FiO2 < 300 mmHg, 'moderate' if 100 <= PaO2/FiO2 < 200 mmHg, 'severe' if PaO2/FiO2 < 100 mmHg. A patient with ARDS (PaO2/FiO2<300 mmHg) is considered 'worsened' in case of a decrease of PaO2/FiO2 of at least one third (-33,3%) from the baseline PaO2/FiO2 value. NOTE that: N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio at each time point is available. While n is the number of subjects worsened at each time point in comparison with the randomization, expressed in percentage. | At day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to Oxygen Delivery System Classification | Duration of oxygen administration (hours) = Administration end date/time - Administration start date/time / 60. N is the number of subjects for which the evaluation of the Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point, expressed in percentage, in comparison with the randomization. According to Oxygen Delivery System, the classification is 'invasive' if there is Invasive Medicinal Ventilation or ECMO, else 'high flow' if there is High Flow Nasal Cannula or BIPAP or CPAP, else 'low flow' if there is Nasal Cannula or Mask then Class=Low Flow Classification. A patient is considered 'Worsened' after baseline if there is an increase in the level of severity within the oxygen delivery system classification (Invasive > High Flow > Low Flow). | day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Oxygen Cumulative Duration During the Study | This outcome assesses the oxygen cumulative duration during the study. N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio or Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point in comparison with the randomization. | Week 1, EOT, EOS |
| Phase 2 - Oxygen Cumulative Quantity During the Study | In this endpoint is assessed the oxygen cumulative quantity needed at each single timepoint. N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio or Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point in comparison with the randomization. | Week 1, EOT and EOS |
| Phase 2 - Percentage of Subjects Requiring Mechanical Ventilation Use, Overall | Percentage along with the 95% confidence interval (Clopper-Pearson's formula) of subjects requiring mechanical ventilation are calculated and compared. N is the number of subjects for which the evaluation of the use of mechanical ventilation is available. n is the number, expressed in percentage, of subjects requiring mechanical ventilation, overall. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Cumulative Duration of Mechanical Ventilation Use, Overall | Cumulative duration of mechanical ventilation (in hours) = Sum of duration of mechanical ventilation (hours) in mechanical ventilation form, from randomization to time point of interest. Duration of mechanical ventilation (hours) = End date/time - Start date/time / 60. n is the number of subjects for which the evaluation of the use of mechanical ventilation is available | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Percentage of Subjects With Intensive Care Unit (ICU) Admission Need | Percentage, along with the 95% confidence interval (Clopper-Pearson's formula), of subjects requiring ICU admission are calculated and compared.N is the number of subjects for which the evaluation of the ICU admission need is available. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Cumulative ICU Stay | Cumulative ICU stay was assessed at different timepoints and measured in days | Day 1, Day 2, Week 1, EOT, EOS |
| Phase 2 - Lung Damage Extension by Severity and by Timepoint | Lung damage extensions is assessed by Chest CT or Rx. This damage can be as follows: "none", "trace", "mild", "moderate", or "severe". N is the number of subjects for which the evaluation of the lung damage extension at each time point is available. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Lung Exudation by Severity and by Timepoint | Lung exudation is assessed by Chest CT or Rx. This can be as follows: "none", "trace", "mild", "moderate", or "severe". N is the number of subjects for which the evaluation of the lung damage extension at each time point is available. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Change From Baseline in Partial Arterial Oxygen Pressure (PaO2) | PaO2 measures the pressure of oxygen dissolved in the blood and how well oxygen is able to move from the airspace of the lungs into the blood. Normally, PaO2 is between 75 and 100 mmHg (at sea level). Lower levels indicate an unsufficient amount of oxygen flowing from the alveoli to the blood. Please note that a significant proportion of patients in both groups did not have post-baseline assessments of PaO2. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Change From Baseline in Oxygen Saturation (SpO2) | SpO2 measures the amount of oxygen-carrying hemoglobin in the blood relative to the amount of hemoglobin not carrying oxygen. Acceptable normal ranges for patients without pulmonary pathology are from 95 to 99 percent. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Partial Arterial Oxygen Pressure (PaO2) to Fraction of Inspiration O2 (FiO2) Ratio [PaO2/FiO2 Ratio] | PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage) also known as the Horowitz index, the Carrico index, and (most conveniently) the P/F ratio at sea level, the normal PaO2/FiO2 ratio is ~ 400-500 mmHg (~55-65 kPa). | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Phase 2 - Change From Baseline in Reactive Protein (CRP) | For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). Levels between 10 mg/L and 100 mg/L are moderately elevated and are usually due to more significant inflammation from an infectious or non-infectious cause. Inflammatory status is documented by C-reactive protein (CRP) ≥ 100mg/L. | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
| Ospedale San Paolo |
| Milan |
| Lombardy |
| 20100 |
| Italy |
| Ospedale San Raffaele | Milan | Lombardy | 20100 | Italy |
| Ospedale di Varese | Varese | Lombardy | Italy |
| Withdrawal by Subject |
|
| Physician Decision |
|
| Patient transferred to another centre for oxygen rehabilitation |
|
| Refused to continue the treatment |
|
| Patient admitted to ICU |
|
| BG001 |
| Standard of Care (FAS) |
Standard of care Standard of care: Standard of care |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Reparixin (FAS) |
Reparixin oral tablets 1200 mg TID for 7 days Reparixin: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first. |
| OG001 | Standard of Care (FAS) | Standard of care Standard of care: Standard of care |
|
|
|
| Secondary | Phase 2 - Percentage of Patients With Improvement in Clinical Severity Score (as Recommended by WHO for COVID Studies) of at Least Two Points | Changes in clinical severity score are defined as the time to clinical improvement of two points from the time of randomization on a seven-category ordinal scale or live discharge from the hospital, whichever came first. The seven-category ordinal scale consisted of the following: 1) not hospitalized, with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring supplemental oxygen; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, requiring high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6) hospitalized, requiring Extracorporeal Membrane Oxygenation (ECMO), invasive mechanical ventilation, or both; and 7) death. The higher the score, the worse the outcome. A subject is considered "improved" with a clinical severity score improvement of at least two points compared to randomization or live discharge from the hospital. n are the subjects improved at each time point vs baseline. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | 95% Confidence Interval | Percentage of patients | At day 1, day 2, week 1, day 21(end of treatment, EOT), EOS (end of study, i.e. 7±3 days after EOT) |
|
|
|
|
| Secondary | Phase 2 - Percentage of Improved Subjects in Dyspnea Severity, Assessed by Liker Scale | The severity of dyspnea can be measured through the Liker scale. The Liker scale is used as follows: the patient grades his current breathing compared to when he first started the drug (from -3 to 3). "0" = no change, "1" =minimally better, "2" =moderately better, "3" =markedly better, "-1" =minimally worse, "-2" =moderately worse, "-3" =markedly worse. The higher the score, the better the outcome. N is the number of subjects for which the evaluation of the dyspnea severity scale at each time point is available. n is the number of subjects improved at each time point in comparison with the randomization. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Count of Participants | Participants | Baseline, day 1, day 2, week 1, day 21(end of treatment, EOT), 7±3 days after treatment period (end of study, EOS) |
|
|
|
|
| Secondary | Phase 2 - Change From Baseline in Dyspnea Severity, Assessed by VAS Scale | The severity of dyspnea is measured also through the VAS scale. The VAS scale is used as follows: the patient draws a horizontal line on an axial graph (from 0 to 100) to show the degree of how he feels about breathing. The number "0" equals the worst breathing the patient has ever felt and the number "100" equals the best he has ever felt. N is the number of subjects for which the evaluation of the dyspnea severity scale at each time point is available. n is the number of subjects improved at each time point in comparison with the randomization. | The Full Analysis Set (FAS) consisted of all randomized subjects who received at least one dose of the IMP. Please note that N (36 for Reparixin and 19 for SoC) is the number of subjects for which the evaluation of the dyspnea severity scale at each time point is available. n - hereunder reported (28 for Reparixin and 19 for SoC) - is the number of subjects improved at each time point in comparison with the randomization. | Posted | Mean | Standard Deviation | score on a scale | Baseline, day 1, day 2, week 1, day 21(end of treatment, EOT), 7±3 days after treatment period (end of study, EOS) |
|
|
|
|
| Secondary | Changes From Baseline in Body Temperature to Any Post-baseline Timepoints | Variations in the mean body temperature from baseline to any post-baseline timepoint were assessed. n is the number of subjects for which the evaluation of the body temperature at each time point is available. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | F° | Baseline, Day 1, Day 2, Week 1, EOT and EOS |
|
|
|
|
| Secondary | Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to PaO2/FiO2 | Cumulative quantity of oxygen treatment (L) = Sum of all Quantity (L) in CONCOMITANT OXYGEN TREATMENT form, from randomization to time point of interest. According to PaO2/FiO2, the classification is 'mild' if 200 <= PaO2/FiO2 < 300 mmHg, 'moderate' if 100 <= PaO2/FiO2 < 200 mmHg, 'severe' if PaO2/FiO2 < 100 mmHg. A patient with ARDS (PaO2/FiO2<300 mmHg) is considered 'worsened' in case of a decrease of PaO2/FiO2 of at least one third (-33,3%) from the baseline PaO2/FiO2 value. NOTE that: N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio at each time point is available. While n is the number of subjects worsened at each time point in comparison with the randomization, expressed in percentage. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | 90% Confidence Interval | percentage of subjects | At day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to Oxygen Delivery System Classification | Duration of oxygen administration (hours) = Administration end date/time - Administration start date/time / 60. N is the number of subjects for which the evaluation of the Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point, expressed in percentage, in comparison with the randomization. According to Oxygen Delivery System, the classification is 'invasive' if there is Invasive Medicinal Ventilation or ECMO, else 'high flow' if there is High Flow Nasal Cannula or BIPAP or CPAP, else 'low flow' if there is Nasal Cannula or Mask then Class=Low Flow Classification. A patient is considered 'Worsened' after baseline if there is an increase in the level of severity within the oxygen delivery system classification (Invasive > High Flow > Low Flow). | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | 95% Confidence Interval | percentage of patients | day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Oxygen Cumulative Duration During the Study | This outcome assesses the oxygen cumulative duration during the study. N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio or Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point in comparison with the randomization. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | hours | Week 1, EOT, EOS |
|
|
|
|
| Secondary | Phase 2 - Oxygen Cumulative Quantity During the Study | In this endpoint is assessed the oxygen cumulative quantity needed at each single timepoint. N is the number of subjects for which the evaluation of the PaO2/FiO2 ratio or Oxygen Delivery System Classification at each time point is available. n is the number of subjects worsened at each time point in comparison with the randomization. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | liters | Week 1, EOT and EOS |
|
|
|
|
| Secondary | Phase 2 - Percentage of Subjects Requiring Mechanical Ventilation Use, Overall | Percentage along with the 95% confidence interval (Clopper-Pearson's formula) of subjects requiring mechanical ventilation are calculated and compared. N is the number of subjects for which the evaluation of the use of mechanical ventilation is available. n is the number, expressed in percentage, of subjects requiring mechanical ventilation, overall. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | 95% Confidence Interval | percentage of subjects | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Cumulative Duration of Mechanical Ventilation Use, Overall | Cumulative duration of mechanical ventilation (in hours) = Sum of duration of mechanical ventilation (hours) in mechanical ventilation form, from randomization to time point of interest. Duration of mechanical ventilation (hours) = End date/time - Start date/time / 60. n is the number of subjects for which the evaluation of the use of mechanical ventilation is available | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | hours | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Percentage of Subjects With Intensive Care Unit (ICU) Admission Need | Percentage, along with the 95% confidence interval (Clopper-Pearson's formula), of subjects requiring ICU admission are calculated and compared.N is the number of subjects for which the evaluation of the ICU admission need is available. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | 95% Confidence Interval | percentage of patients | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Cumulative ICU Stay | Cumulative ICU stay was assessed at different timepoints and measured in days | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Median | Full Range | days | Day 1, Day 2, Week 1, EOT, EOS |
|
|
|
| Secondary | Phase 2 - Lung Damage Extension by Severity and by Timepoint | Lung damage extensions is assessed by Chest CT or Rx. This damage can be as follows: "none", "trace", "mild", "moderate", or "severe". N is the number of subjects for which the evaluation of the lung damage extension at each time point is available. | The Full Analysis Set (FAS) consisted of all randomized subjects who received at least one dose of the IMP. Please note that N, hereunder reported, is the number of subjects for which the evaluation of the lung damage extension or lung damage exudation degree at each time point is available (very low at Day 1 and EOS time points in the "Reparixin" Arm and at the Day 1, 2, and Week 1 time points in the "Standard of Care" Arm). | Posted | Number | participants | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Lung Exudation by Severity and by Timepoint | Lung exudation is assessed by Chest CT or Rx. This can be as follows: "none", "trace", "mild", "moderate", or "severe". N is the number of subjects for which the evaluation of the lung damage extension at each time point is available. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Number | participants | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Change From Baseline in Partial Arterial Oxygen Pressure (PaO2) | PaO2 measures the pressure of oxygen dissolved in the blood and how well oxygen is able to move from the airspace of the lungs into the blood. Normally, PaO2 is between 75 and 100 mmHg (at sea level). Lower levels indicate an unsufficient amount of oxygen flowing from the alveoli to the blood. Please note that a significant proportion of patients in both groups did not have post-baseline assessments of PaO2. | The Full Analysis Set (FAS) consisted of all randomized subjects who received at least one dose of the IMP. Please note that N, hereunder reported, is the number of subjects for which the evaluation of the PaO2 at each time point is available (very low at Day 1 and EOS time points in the "Reparixin" Arm and at the Day 1, 2, and Week 1 time points in the "Standard of Care" Arm). | Posted | Mean | Standard Deviation | mmHg | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Change From Baseline in Oxygen Saturation (SpO2) | SpO2 measures the amount of oxygen-carrying hemoglobin in the blood relative to the amount of hemoglobin not carrying oxygen. Acceptable normal ranges for patients without pulmonary pathology are from 95 to 99 percent. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | percent of oxygen saturation | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Partial Arterial Oxygen Pressure (PaO2) to Fraction of Inspiration O2 (FiO2) Ratio [PaO2/FiO2 Ratio] | PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage) also known as the Horowitz index, the Carrico index, and (most conveniently) the P/F ratio at sea level, the normal PaO2/FiO2 ratio is ~ 400-500 mmHg (~55-65 kPa). | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | ratio | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| Secondary | Phase 2 - Change From Baseline in Reactive Protein (CRP) | For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). Levels between 10 mg/L and 100 mg/L are moderately elevated and are usually due to more significant inflammation from an infectious or non-infectious cause. Inflammatory status is documented by C-reactive protein (CRP) ≥ 100mg/L. | The Full Analysis Set (FAS), which consisted of all randomized subjects who received at least one dose of the IMP. The FAS population was analyzed according to intention to treat (ITT) principle, i.e. by treatment allocation regardless the occurrence of intercurrent events. The FAS population was used for the primary analyses of the study and to present results on efficacy data; | Posted | Mean | Standard Deviation | mg/L | Baseline, day 1, day 2, week 1, day 21(end of treatment), follow-up (FU) (7±3 days after treatment period) |
|
|
|
|
| 1 |
| 36 |
| 1 |
| 36 |
| 1 |
| 36 |
| EG001 | Standard of Care (SAF) | Standard of care, which is defined as any drug currently used to treat the COVID-19 pneumonia. | 3 | 19 | 1 | 19 | 1 | 19 |
| Post procedural discomfort | Injury, poisoning and procedural complications | MedDRA 23.1 | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
|
Not provided
Not provided
| D011024 |
| Pneumonia, Viral |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| Day 2 |
|
|
| Week 1 |
|
|
| EOT |
|
|
| EOS |
|
|
| 1.000 |
| Superiority |
| at EOS | Fisher Exact | 1.000 | Superiority |
| Day 1 |
|
|
| Day 2 |
|
|
| Week 1 |
|
|
| EOT |
|
|
| EOS |
|
|
| 0.401 |
| Superiority |
| At Day 2 | Fisher Exact | 0.066 | Superiority |
| At week 1 | Fisher Exact | 0.102 | Superiority |
| at EOT | Fisher Exact | 0.314 | Superiority |
| at EOS | Fisher Exact | 1.000 | Superiority |
| to Day 1 |
|
|
| to Day 2 |
|
|
| Week 1 |
|
|
| EOT |
|
|
| EOS |
|
|
| Wilcoxon (Mann-Whitney) |
| >0.999 |
p-values are referred to a two-sided Wilcoxon test for differences in the change of VAS scale. |
| Superiority |
| week 1 vs baseline | Wilcoxon (Mann-Whitney) | 0.050 | p-values are referred to a two-sided Wilcoxon test for differences in the change of VAS scale. | Superiority |
| EOT vs baseline | Wilcoxon (Mann-Whitney) | 0.0227 | p-values are referred to a two-sided Wilcoxon test for differences in the change of VAS scale. | Superiority |
| to Day 1 |
|
|
| to Day 2 |
|
|
| to Week 1 |
|
|
| to EOT |
|
|
| to EOS |
|
|
| 0.985 |
| Superiority |
| at week 1 | Wilcoxon (Mann-Whitney) | 0.857 | Superiority |
| at EOT | Wilcoxon (Mann-Whitney) | 0.436 | Superiority |
| At EOS | Wilcoxon (Mann-Whitney) | 0.350 | Superiority |
| Day 2 - subjects worsened (%) |
|
|
| Week 1 - subjects worsened (%) |
|
|
| EOT - subjects worsened (%) |
|
|
| EOS - subjects worsened (%) |
|
|
| 0.667 |
| Superiority |
p-values are referred to a two-sided Fisher's Exact test for worsening |
| Week 1 | Fisher Exact | 0.037 | Superiority | p-values are referred to a two-sided Fisher's Exact test for worsening |
| EOT | Fisher Exact | 0.293 | p-values are referred to a two-sided Fisher's Exact test for worsening | Superiority | p-values are referred to a two-sided Fisher's Exact test for worsening |
| Day 2 - subjects worsened |
|
|
| Week 1 - subjects worsened |
|
|
| EOT - subjects worsened |
|
|
| EOS - subjects worsened |
|
|
| 1.000 |
p-values are referred to a two-sided Fisher's Exact test for worsening |
| Superiority |
| Week 1 | Fisher Exact | 0.102 | p-values are referred to a two-sided Fisher's Exact test for worsening | Superiority |
| EOT | Fisher Exact | 0.119 | p-values are referred to a two-sided Fisher's Exact test for worsening | Superiority |
| EOS | Fisher Exact | 0.515 | p-values are referred to a two-sided Fisher's Exact test for worsening | Superiority |
| EOT |
|
|
| EOS |
|
|
| 0.489 |
p-values are referred to a two-sided Wilcoxon test for cumulative duration. |
| Superiority |
| EOS | Wilcoxon (Mann-Whitney) | 0.486 | p-values are referred to a two-sided Wilcoxon test for cumulative duration. | Superiority |
| EOT |
|
|
| EOS |
|
|
| 0.961 |
p-values are referred to a two-sided Wilcoxon test for cumulative quantity |
| Superiority |
| EOS | Wilcoxon (Mann-Whitney) | 0.619 | p-values are referred to a two-sided Wilcoxon test for cumulative quantity | Superiority |
| Day1 - subjects requiring |
|
|
| Day 2 - subjects requiring |
|
|
| Week 1- subjects requiring |
|
|
| EOT - subjects requiring |
|
|
| EOS -subjects requiring |
|
|
| 1.000 |
p-values are referred to a two-sided Fisher's Exact test for proportion |
| Superiority |
| Day 2 | Fisher Exact | 0.678 | p-values are referred to a two-sided Fisher's Exact test for proportion | Superiority |
| Week 1 | Fisher Exact | 1.000 | p-values are referred to a two-sided Fisher's Exact test for proportion | Superiority |
| EOT | Fisher Exact | 1.000 | p-values are referred to a two-sided Fisher's Exact test for proportion | Superiority |
| EOS | Fisher Exact | 1.000 | p-values are referred to a two-sided Fisher's Exact test for proportion | Superiority |
| EOT |
|
|
| EOS |
|
|
| >0.999 |
p-values are referred to a-sided Wilcoxon test for cumulative duration |
| Superiority |
| EOS | Wilcoxon (Mann-Whitney) | 0.596 | p-values are referred to a-sided Wilcoxon test for cumulative duration | Superiority |
| Day 1 - subjects admitted to ICU |
|
|
| Day 2 - subjects admitted to ICU |
|
|
| Week 1 - subjects admitted to ICU |
|
|
| EOT - subjects admitted to ICU |
|
|
| EOS - subjects admitted to ICU |
|
|
p-values are referred to a two-sided Fisher's Exact test for proportion |
| 1.000 |
| Superiority |
| Day 2 | Fisher Exact | p-values are referred to a two-sided Fisher's Exact test for proportion | 1.000 | Superiority |
| week 1 | Fisher Exact | p-values are referred to a two-sided Fisher's Exact test for proportion | 1.000 | Superiority |
| EOT | Fisher Exact | 1.000 | p-values are referred to a two-sided Fisher's Exact test for proportion | Superiority |
| Day 2 - cumulative ICU stay |
|
|
| Week 1 - cumulative ICU stay |
|
|
| EOT - cumulative ICU stay |
|
|
| EOS - cumulative ICU stay |
|
|
| baseline - trace |
|
|
| baseline - mild |
|
|
| baseline - moderate |
|
|
| baseline - severe |
|
|
| Day 1 - none |
|
|
| Day 1 - trace |
|
|
| Day 1 - mild |
|
|
| Day 1 - moderate |
|
|
| Day 1 - severe |
|
|
| Day 2 - none |
|
|
| Day 2 - trace |
|
|
| Day 2 - mild |
|
|
| Day 2 - moderate |
|
|
| Day 2 - severe |
|
|
| week 1 - none |
|
|
| week 1- trace |
|
|
| week 1 - mild |
|
|
| week 1 - moderate |
|
|
| week 1 - severe |
|
|
| EOT - none |
|
|
| EOT - trace |
|
|
| EOT - mild |
|
|
| EOT - moderate |
|
|
| EOT - severe |
|
|
| EOS - none |
|
|
| EOS - trace |
|
|
| EOS - mild |
|
|
| EOS - moderate |
|
|
| EOS - severe |
|
|
| 0.394 |
p-values are referred to a two-sided Wilcoxon test |
| Superiority |
| EOT | Wilcoxon (Mann-Whitney) | 0.141 | p-values are referred to a two-sided Wilcoxon test | Superiority |
| EOS | Wilcoxon (Mann-Whitney) | >0.999 | p-values are referred to a two-sided Wilcoxon test | Superiority |
| baseline - trace |
|
|
| baseline - mild |
|
|
| baseline - moderate |
|
|
| baseline - severe |
|
|
| Day 1 - none |
|
|
| Day 1 - trace |
|
|
| Day 1 - mild |
|
|
| Day 1 - moderate |
|
|
| Day 1 - severe |
|
|
| Day 2 - none |
|
|
| Day 2 - trace |
|
|
| Day 2 - mild |
|
|
| Day 2 - moderate |
|
|
| Day 2 - severe |
|
|
| week 1 - none |
|
|
| week 1- trace |
|
|
| week 1 - mild |
|
|
| week 1 - moderate |
|
|
| week 1 - severe |
|
|
| EOT - none |
|
|
| EOT - trace |
|
|
| EOT - mild |
|
|
| EOT - moderate |
|
|
| EOT - severe |
|
|
| EOS - none |
|
|
| EOS - trace |
|
|
| EOS - mild |
|
|
| EOS - moderate |
|
|
| EOS - severe |
|
|
| 0.112 |
p-values are referred to a two-sided Wilcoxon test. |
| Superiority |
| EOT | Wilcoxon (Mann-Whitney) | 0.277 | p-values are referred to a two-sided Wilcoxon test. | Superiority |
| EOS | Wilcoxon (Mann-Whitney) | >0.999 | p-values are referred to a two-sided Wilcoxon test. | Superiority |
| to Day 1 |
|
|
| to Day 2 |
|
|
| to week 1 |
|
|
| to EOT |
|
|
| to EOS |
|
|
| Wilcoxon (Mann-Whitney) |
| 1.0000 |
p-values are referred to a two-sided Wilcoxon test for differences in the change |
| Superiority |
| Week 1 vs baseline | Wilcoxon (Mann-Whitney) | 0.4469 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| EOT vs baseline | Wilcoxon (Mann-Whitney) | 0.2466 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| EOS vs baseline | Wilcoxon (Mann-Whitney) | 0.1752 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| to Day 1 |
|
|
| to Day 2 |
|
|
| to week 1 |
|
|
| to EOT |
|
|
| to EOS |
|
|
| Wilcoxon (Mann-Whitney) |
| 0.3529 |
p-values are referred to a two-sided Wilcoxon test for differences in the change. |
| Superiority |
| week 1 vs baseline | Wilcoxon (Mann-Whitney) | 0.3581 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |
| EOT vs baseline | Wilcoxon (Mann-Whitney) | 0.1666 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |
| EOS vs baseline | Wilcoxon (Mann-Whitney) | 0.0851 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |
| To day 1 |
|
|
| To day 2 |
|
|
| To week 1 |
|
|
| To EOT |
|
|
| To EOS |
|
|
| Wilcoxon (Mann-Whitney) |
| 0.3136 |
p-values are referred to a two-sided Wilcoxon test for differences in the change |
| Superiority |
| week 1 vs baseline | Wilcoxon (Mann-Whitney) | 0.0441 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| EOT vs baseline | Wilcoxon (Mann-Whitney) | 0.0965 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| EOS vs baseline | Wilcoxon (Mann-Whitney) | 0.0519 | p-values are referred to a two-sided Wilcoxon test for differences in the change | Superiority |
| to day 1 |
|
|
| to day 2 |
|
|
| to week 1 |
|
|
| to EOT |
|
|
| to EOS |
|
|
| Wilcoxon (Mann-Whitney) |
| 0.425 |
p-values are referred to a two-sided Wilcoxon test for differences in the change. |
| Superiority |
| week 1 vs baseline | Wilcoxon (Mann-Whitney) | 0.086 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |
| EOT vs baseline | Wilcoxon (Mann-Whitney) | 0.600 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |
| EOS vs baseline | Wilcoxon (Mann-Whitney) | 0.717 | p-values are referred to a two-sided Wilcoxon test for differences in the change. | Superiority |